FOM and labeling with PE-conjugated anti-EGFR AY13 (3-day treatment) and anti-EpCAM 9C4 (6-day treatment) mAbs identified additional CAM specimens bearing macroscopically invisible vital tumor microresidues (Table 2). This evidence concerns the gene EPCAM and neoplasm.